Media Coverage

FDA clears J&J's esketamine in treatment-resistant depression, with restrictions as per REMS

FDA clears J&J's esketamine in treatment-resistant depression, with restrictions as per REMS

Mar 7, 2019

J&J's ketamine-based drug drives sea change for new depression treatments

J&J's ketamine-based drug drives sea change for new depression treatments

Mar 7, 2019

Seeking a Cure: VistaGen Therapeutics' Potential Anti-Depression Drug

Seeking a Cure: VistaGen Therapeutics' Potential Anti-Depression Drug

Mar 6, 2019

FDA approves Spravato nasal spray for depression

FDA approves Spravato nasal spray for depression

Mar 6, 2019

BioSpace's Global Biopharma Roundup: February 21

BioSpace's Global Biopharma Roundup: February 21

Feb 21, 2019

J&J nears FDA approval for landmark depression drug to replace ketamine treatments

J&J nears FDA approval for landmark depression drug to replace ketamine treatments

Feb 13, 2019

Can We Treat Mood Disorders With Pharmacological Therapeutics?

Can We Treat Mood Disorders With Pharmacological Therapeutics?

Feb 1, 2019

Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

Jan 16, 2019

VistaGen CEO notes broad market potential of ketamine-like AV-101

VistaGen CEO notes broad market potential of ketamine-like AV-101

Nov 26, 2018

Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more

Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more

Oct 29, 2018